Scribe Therapeutics, Inc.

Scribe Therapeutics, Inc. (SCTX) priced its initial public offering on Jul 27, 2026 at $15.00 per share, within its $13.00–$15.00 range, raising $128.7M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $263.7M. Fenwick & West advised the company and Latham & Watkins advised the underwriters.

Scribe Therapeutics, Inc. is a clinical-stage biotechnology company engineering in vivo CRISPR technologies intended to extend healthy lifespan through disease prevention and durable therapeutic intervention, including in common diseases.

Status

IPO

Ticker

SCTX

Exchange

Nasdaq Global Market

Priced

Jul 27, 2026

IPO price

$15.00

Price range

$13.00–$15.00

Raised

$128.7M

Market cap at IPO price

$263.7M

First filed

Jul 2, 2026

Company counsel

Fenwick & West

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.